12
Participants
Start Date
November 30, 2010
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
AEZS-108
128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
AEZS-108 at MTD
2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
Univerity of Pennsylvania, Philadelphia
University of Miami Miller School of Medicine, Miami
Lead Sponsor
University of Miami
OTHER
Miami VA Healthcare System
FED
University of Miami Sylvester Comprehensive Cancer Center
OTHER
AEterna Zentaris
INDUSTRY